Home
Innovative Antibacterial Drugs
BioVersys GmbH is a Swiss biopharmaceutical company that focuses on research and development of new drugs and compounds, which switch-off drug resistance within the pathogen and render antibiotics effective again. Being an ETH-Zurich spin-off company we rely on our profound technological expertise, that is reflected by numerous patents and publications.
Market
The market for antibiotics represents, with close to 27 billion USD, one of the largest categories of biopharmaceutical therapeutics. While the identification of de novo antibiotic compounds dramatically slowed down since 1960 and the focus shifted to modifications of existing antibiotic-families, we believe that the successful therapeutic treatment of bacterial infections, especially infections caused by multi-resistant strains, in the close future will strongly benefit from dual-intervention strategies, like followed by BioVersys GmbH.